bluuebunny/crossref_metadata_2025_split huggingface dataset:
Effects of early recurrence and extra-PV triggers on long-term recurrence after catheter ablation for atrial fibrillation
Authors: Park Y , Yu H T , Kim T H , Uhm J S , Joung B , Lee M H , Pak H N 
Published: October 2022

Abstract

Background
Although early recurrence (ER) within 3 months after atrial fibrillation (AF) catheter ablation (AFCA) was recently reported to be a reliable predictor of late recurrence (LR), the mechanism is not clear.

Purpose
We explored the characteristics of patients with ER and compared the long-term late recurrence (LR) pattern depending on the existence of extra-pulmonary vein trigger (ExPV-trigger).

Methods
Among 3643 patients who underwent de novo AFCA, we included 1249 patients (59.2±11.0 years old, 31.3% persistent AF) who underwent isoproterenol provocation and regular follow-up over three years after AFCA. We evaluated the risk factors for ER and compared the patients with ER alone (10.1%), LR alone (16.6%), and ER+LR (15.9%), and the outcome of repeat procedure.

Results
Overall ER (ER alone and ER+LR) was independently associated with persistent AF (OR 1.58 [1.16–2.14], p=0.003), extra-PV triggers (OR 2.80 [1.90–4.13], p&lt;0.001), and empirical extra-PV ablation (OR 1.54 [1.15–2.07], p=0.004). Overall LR (LR alone and ER+LR) risk was significantly higher in the ER with ExPV-trigger group than in ER without ExPV-trigger or no ER groups (Log-rank p&lt;0.001). The rhythm outcome of the second procedure did not differ between ER+LR and LR alone groups (Log-rank p=0.160), but was worse in the ER+LR ExPV-trigger than in ER+LR without ExPV-trigger or LR alone groups (Log-rank p=0.005).

Conclusion
ER was independently associated with LR after de novo AFCA. ExPV-trigger played crucial roles in ER and LR after de novo AFCA and worse rhythm outcome after redo AFCA.

Funding Acknowledgement
Type of funding sources: None.
Effect of the epicardial fat volume on the outcomes after a left atrial posterior wall isolation in addition to pulmonary vein isolation in patients with persistent atrial fibrillation
Authors: Kim D , Yu H T , Kwon O S , Kim T H , Uhm J S , Joung B , Lee M H , Pak H N 
Published: October 2022

Abstract

Background
While the effect of a circumferential pulmonary vein isolation (CPVI) alone is unsatisfactory, that of an additional electrical posterior wall box isolation (POBI) is controversial in persistent atrial fibrillation (PeAF) patients. Increased epicardial adipose tissue (EAT) is associated with higher recurrence rates after AF catheter ablation (AFCA).

Purpose
We investigated the possible effects of a POBI on rhythm outcomes with varying EAT volumes.

Methods
We included 1,187 patients with PeAF undergoing a de novo AFCA (79.6% male, median age 60 years) into two groups including those receiving a CPVI alone (n=687) and those an additional POBI (n=500). The rhythm outcomes at two years post-AFCA were compared in subgroups stratified by the total EAT volume using propensity overlap weighting.

Results
A reduced total EAT volume was linearly associated with more favorable rhythm outcomes for an additional POBI treatment than for a CPVI alone (P for interaction=0.002). Among the patients with smaller EAT volumes (≤116.23 ml, the median value, n=594), an additional POBI was associated with a reduced AF recurrence risk as compared to a CPVI only (weighted hazard ratio [HR] 0.74, 95% confidence interval [CI] 0.56–0.99; weighted log-rank P=0.039). In contrast, among the remaining 593 patients with greater EAT volumes (&gt;116.2 3mL), there was no difference in the AF recurrence risk between an additional POBI and CPVI alone (weighted HR 1.13, 95% CI 0.84–1.52; weighted log-rank P=0.410). Among 185 patients with a repeat ablation, the POBI reconnection rate tended to be higher in the large EAT group (75.0%) than small EAT group (55.4%, P=0.060).

Conclusion
While PeAF patients with a smaller EAT volume averted AF recurrence by an additional POBI after the CPVI, no benefit of the POBI was observed in those with a greater EAT volume. The EAT volume might identify AF patients likely to benefit from linear ablation in addition to the CPVI.

Funding Acknowledgement
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Korean Ministry of Science, ICT & Future Planning (MSIP)Korean Ministry of Health and Welfare
Patient age, gender, and early outcome after PVI atrial ablation: analysis of a large regional database
Authors: Cooper J , Joseph C , Xiong T , Brar D , Kostov V , Kulstad E , Daniels J 
Published: October 2022

Abstract

Background
Demographics such as patient age and gender have been inconsistently found to be associated with outcome after ablation to achieve pulmonary vein isolation (PVI). A database created by the Dallas-Fort Worth Hospital Council (DFWHC) includes a collaboration of 90 member hospitals in North Texas reporting data on procedures, diagnoses, and discharges. All patients in this system can be followed longitudinally via unique identification number. The availability of this large, regional database offers opportunities to better characterize trends.

Objective
Characterize the association between age, gender, and 60-day outcome in patients receiving PVI over a 7-year time span.

Methods
Using the DFWHC database, all PVI procedures performed from January 2013 to December 2019 were identified. Follow up visits for this cohort of patients were then obtained, and outcomes recorded. Early mortalities (occurring less than 60 days from PVI), mean age and patient gender were determined for each of the groups and compared.

Results
A total of 11,880 unique PVI procedures were performed over this 7 year timeframe. Mean patient age was 64±10 years, with 66% male and 34% female. A total of 130 mortalities at any time after PVI occurred (1.1%), with 19 (0.16%) occurring within 60 days of the procedure. In multivariate analysis, the risk of 60-day mortality increased with year of procedure (OR 1.07, 95% CI 0.85 to 1.4) and female gender (OR 1.43, 95% CI 0.57 to 3.6), and decreased with age (OR 0.99, 95% CI 0.95 to 1.03); however no variable demonstrated statistically significant association with outcome.

Conclusions
Although trends towards increasing mortality over time and in female patients were seen, the total number of events remained low, and no statistically significant associations between age, gender, and early mortality were identified in this large regional database.

Funding Acknowledgement
Type of funding sources: None.
Variations in atrial fibrillation screening after ischemic stroke or transient ischemic attack in Sweden
Authors: Straat K , Wester P , Svennberg E , Anggardh Rooth E , Laska A C , Asberg S , Engdahl J 
Published: October 2022

Abstract

Background/Introduction
The risk of recurrent stroke and mortality is high among patients with ischemic stroke or transient ischemic attack (TIA) and untreated atrial fibrillation (AF). Hence, AF screening after an event has high priority in national and international guidelines. Despite the abundance of evidence on AF detection using different AF screening modalities, there is still no evidence on a prognostic benefit of ECG monitoring post ischemic stroke. There is a risk for variations in clinical practice for AF screening after ischemic cerebrovascular events due to this gap of evidence.

Purpose
The aim of this study was to investigate the clinical practice of AF screening after TIA or ischemic stroke at Swedish stroke units.

Methods
In collaboration with the stakeholders of the Swedish stroke register (Riksstroke) important fields to study were identified, e.g. AF screening method, first choice of method (multiple answers possible), monitoring duration, clinical follow-up etc. A draft for a digital survey was constructed and then tested and revised by 5 stroke consultants. The survey consisted of 18 multiple choice questions with free text comments and was sent by e-mail to the medical supervisors at all stroke units in Sweden in November 2021.

Results
All 72 stroke units in Sweden responded to the survey. Almost all (69/72) stroke units reported that ≥75% of ischemic stroke patients are screened for AF. Of the stroke units 81% had inpatient telemetry as their first choice of AF screening method (Figure 1), but 7% had no access to inpatient telemetry. In case of inpatient telemetry, 30% reported 0–24 hours and 54% reported 24–48 hours as their standard monitoring time. Most had the attending physician at the stroke unit as the primary ECG reader, some with access to support from cardiologist. Different standard monitoring durations for Holter were used (Figure 2) and 17% reported Holter as their first choice of AF screening method. Approximately 85% reported repeated ECG monitoring if high suspicion of cardiac embolization, preferably with repeated Holter (73%) or handheld ECG (49%). Implantable loop recorder (6%), event loop recorder (14%) and 2 weeks registration with ECG-patch (3%) was more infrequently used for this purpose.

Conclusions
Clinical practice for AF screening after ischemic stroke or TIA at Swedish stroke units showed considerable variations with a range of different AF screening methods and monitoring durations. Further, the standards and quality of inpatient ECG monitoring is unknown. There is an urgent need for evidence and evidence-based recommendations in this field, the present situation also implies inequality in care.

Funding Acknowledgement
Type of funding sources: Foundation. Main funding source(s): Stiftelsen Hjartat
Should we initiate oral anticoagulants for patients with atrial fibrillation staying well without oral anticoagulants for years?
Authors: Chao T , Lip G Y H , Chen S A 
Published: October 2022

Abstract

Background
Although non-vitamin K antagonist oral anticoagulants (NOACs) were more and more commonly prescribed for stroke prevention for patients with atrial fibrillation (AF), underuse of OACs is still not uncommon. Data about the initiations of OACs in AF patients who did not experience ischemic stroke without any OACs for years since incident AF was diagnosed were limited. We aimed to investigate the associations between the initiations of warfarin or NOACs and clinical outcomes among this population.

Methods
From January 1st, 2007 to December 31st, 2010, a total of 167,176 newly-diagnosed AF patients aged ≥20 years were identified from the Taiwan National Health Insurance Research Database as the study population. Among the study population, 32,917 patients with a CHA2DS2-VASc score &gt;1 for males or &gt;2 for females who did not receive warfarin or NOACs and survived for at least 90 days after June 1st, 2015 were defined as the “original non-OAC cohort”. These patients were then categorized into 3 groups according to the stroke prevention strategies they received after June 1st, 2015; that is, without OACs (n=31,195), warfarin (n=230) and NOACs (n=1,492).

Results
Compared to patients staying on non-OACs, the risk of ischemic stroke was lower for patients who initiated NOACs (aHR 0.867; p=0.043). The risk of all-cause mortality was lower for patients who started to receive warfarin (aHR 0.876; p=0.036) or NOACs (aHR 0.798; p=0.047). The composite risk of ischemic stroke or major bleeding was also lower for patients who initiated warfarin (0.849; p&lt;0.001) or NOACs (0.789; p&lt;0.001) (Figure 1). Compared to warfarin, NOACs use was associated with a lower risk of ischemic stroke (aHR 0.819; p&lt;0.001), ischemic stroke or intracranial hemorrhage (aHR 0.927; p=0.042) or ischemic stroke or major bleeding (aHR 0.912; p&lt;0.001).

Conclusions
Initiations of OACs, especially NOACs, should still be considered for AF patients who stayed well without OACs for years since incident AF was diagnosed.

Funding Acknowledgement
Type of funding sources: None.
Clinical phenotypes of older adults with non-valvular atrial fibrillation not treated with oral anticoagulants by hierarchical cluster analysis in the ANAFIE registry
Authors: Suzuki S , Yamashita T 
Published: October 2022

Abstract

Background and purpose
The All Nippon AF In the Elderly (ANAFIE) registry evaluated the current status of anticoagulant therapy in older adult patients (aged ≥75 years) with non-valvular atrial fibrillation (NVAF) in Japan. Although older adult NVAF patients requires anticoagulation therapy, some of them do not receive it and the reasons would be diverse. Therefore, we aimed to identify the phenotypes of older adult NVAF patients not treated with oral anticoagulants using data from the ANAFIE registry.

Methods
In this sub-analysis of the ANAFIE registry, the phenotypes of patients who were not receiving anticoagulants at baseline were evaluated by cluster analysis using Ward's linkage hierarchical algorithm. We used 20 categorical variables and 6 continuous variables for the cluster analysis which were used as the risk factors in the main analysis of the ANAFIE registry [1].

Results
Of 33,275 enrolled patients, 2445 (7.3%) were not receiving anticoagulants. Two clusters were identified: (1) elderly paroxysmal AF (PAF) patients with a low prevalence of comorbidities (58%) and (2) very elderly patients with a high previous major bleeding prevalence (42%). For each cluster, mean ages were 79.9 and 85.7 years, mean CHADS2 scores were 2.3 and 3.1, PAF prevalences were 83% and 54%, heart failure prevalences were 18% and 48%, the proportions of patients with a history of major bleeding were 0% and 25%, the proportions of patients with a history of catheter ablation were 21% and 8%, respectively. Annual incidence rates of each cluster were 2.62% and 9.08% for all-cause death, 1.72% and 5.83% for major adverse cardiovascular or neurological events, 1.22% and 3.14% for stroke or systemic embolism, and 0.53% and 1.43% for major bleeding.

Conclusions
In this cohort of elderly NVAF patients not receiving anticoagulants, more than half (∼60%) were PAF patients and had a low incidence of adverse outcomes. The remaining ∼40% were characterized as very elderly patients with a high prevalence of previous major bleeding and a high incidence of adverse outcomes.

Funding Acknowledgement
Type of funding sources: Private company. Main funding source(s): Daiichi Sankyo Co., Ltd.
Oral anticoagulation therapy in atrial fibrillation patients with advanced chronic kidney disease: CODE-AF Registry
Authors: Park H , Yu H T , Kim T H , Park J , Park J K , Kang K W , Shim J , Kim J B , Choi E K , Park H W , Lee Y S , Joung B 
Published: October 2022

Abstract

Background and objectives
Advanced chronic kidney disease (CKD), including end-stage renal disease (ESRD) on dialysis, increases thromboembolic risk among patients with atrial fibrillation (AF). This study examined the comparative safety and efficacy of direct-acting oral anticoagulant (DOAC) compared to warfarin or no OAC among AF patients with advanced CKD or ESRD on dialysis.

Methods
Using data from the COmparison study of Drugs for symptom control and complication prEvention of AF (CODE-AF) registry, 260 non-valvular AF patients with advanced CKD (defined as estimated glomerular filtration rate [eGFR] &lt;3 0ml/min per 1.73 m2) or ESRD on dialysis were enrolled from June 2016 to July 2020. The study population was categorized into DOAC, warfarin, and no OAC group, and differences in major or clinically relevant non-major (CRNM) bleeding, stroke/systemic embolism (SE), myocardial infarction/critical limb ischemia (CLI), and death were assessed.

Results
During a median 24 months of follow-up, major or CRNM bleeding risk was significantly reduced in the DOAC group compared to the warfarin group (hazard ratio [HR] 0.21, 95% confidence interval [CI] 0.05 to 0.95, p=0.042). In addition, the risk of composite adverse clinical outcome (major or CRNM bleeding, stroke/SE, myocardial infarction/CLI, and death) was significantly reduced in the DOAC group compared to the no OAC group (HR 0.32, 95% CI 0.11 to 0.96, p=0.043).

Conclusion
Among AF patients with advanced CKD or ESRD on dialysis, DOAC was associated with a lower risk of major or CRNM bleeding compared to warfarin and a lower risk of composite adverse clinical outcome compared to no OAC.

Funding Acknowledgement
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Korean Healthcare Technology R&D project funded by the Ministry of Health & Welfare (HI15C1200, HC19C0130)
Acute and long-term success of left atrial anterior line and mitral isthmus line ablation in patients after mitral valve surgery
Authors: Lemes C , Rottner L , Heeger C H , Maurer T , Reissmann B , Ouyang F , Mathew S , Metzner A , Schlueter M , Kuck K H 
Published: October 2022

Abstract

Background
Perimitral flutter and atrial fibrillation may occur in patients with prior surgical mitral valve (MV) repair or replacement and can be challenging for percutaneous catheter ablation.

Objective
This study sought to determine the feasibility, acute success and durability of catheter ablation of atrial fibrillation or atrial tachycardia by way of a mitral isthmus line (MIL) or an anterior line (AL).

Methods
A total of 81 patients (49 males, mean age 62±11 years) with prior MV replacement (n=30) or repair (n=51) underwent creation of a MIL (n=34) and/or an AL (n=72). Control group patients without prior surgery were matched 1:1 with the valve group (MIL, n=34; AL, n=72).

Results
Acute bidirectional block of the MIL was successfully achieved in 24/34 cases and of the AL in 64/72 patients with prior MV surgery. In the control group, acute bidirectional block was achieved in 31/34 MIL patients and 65/72 AL patients. In terms of durability, the MIL valve subgroup showed the poorest results (probability of long-term failure 2.224, as opposed to 0.605 in the MIL control subgroup; hazard ratio [HR]=0.27, 95% confidence interval [CI], 0.11–0.65; p=0.004). In the AL subgroups, long-term outcomes were similar (probability of failure in AL valve subgroup 0.844 vs. AL control subgroup 1.03; HR=1.22, 95% CI, 0.66–2.26; p=0.523).

Conclusions
Percutaneous creation of MIL and AL is feasible and safe in patients with prior MV replacement/repair. Because of poor long-term outcomes, MIL creation appears not advisable in patient with prior MV surgery.

Funding Acknowledgement
Type of funding sources: None.
Type 2 diabetes is associated with higher risk of 3rd degree atrioventricular block: a Danish nationwide registry study
Authors: Haxha S , Halili A , Malmborg M , Pedersen-Bjergaard U , Philbert B T , Lindhardt T B , Hoejberg S , Schjerning A M , Ruwald M H , Gislason G H , Torp-Pedersen C , Bang C N 
Published: October 2022

Abstract

Background
Type 2 diabetes (T2DM) is suggested to affect the function of the cardiomyocytes and electrical pathways which could cause conduction abnormalities and cardiac arrhythmias, such as 3rd degree atrioventricular block. The association of T2DM and 3rd degree atrioventricular block has never been confirmed in large nationwide studies.

Purpose
To determine the association between T2DM and 3rd degree atrioventricular block.

Method
This nationwide nested case-control study design included patients older than 18 years, diagnosed with 3rd degree atrioventricular block between 1st of July 1995 and 31st of December 2018. Five controls from the risk set of each case of 3rd degree atrioventricular block were matched on age and sex to fit a Cox regression model with time-dependent exposure (T2DM) and time-dependent covariates and baseline hazard function stratified for age and sex. Subgroup analysis was conducted with Cox models for each subgroup.

Results
We identified 31.177 cases with 3rd degree atrioventricular block that were matched with 155.885 controls. The mean age was 78 years and 60% were males. Cases had higher prevalence of T2DM (20% vs 7.8%), hypertension (70% vs 43%) myocardial infarction (16% vs 6.6%), and heart failure (21% vs 5.9%) compared to the control group. In a Cox analysis T2DM was significantly associated with a higher rate of 3rd degree atrioventricular block [HR 2.61 (95% CI: 2.54–2.71)]. The association remained in several subgroup analyses of diseases suspected to be associated with 3rd degree atrioventricular block. There was a significant interaction with sex and age groups and comorbidities of interest including hypertension, atrial fibrillation, heart failure and myocardial infarction (Figure 1).

Conclusion
T2DM is associated with a higher rate of 3rd degree atrioventricular block. The findings were consistent across subgroups.

Funding Acknowledgement
Type of funding sources: Private grant(s) and/or Sponsorship. Main funding source(s): This work was funded by the independent research foundation Skibsreder Per Henrik, R. og Hustrus Fond
Etiologies and predictors for cardiac implantable electronic device implantation in young patients hospitalized for complete atrioventricular block
Authors: Margolis G , Elbaz Greener G , Kazatzker M , Meisel S , Kleiner Shochat M , Heist E K , Ruskin J , Amir O , Roguin A , Rozen G 
Published: October 2022

Abstract

Introduction
Information regarding the etiologies of complete atrioventricular block (CAVB) in young patients is scarce. We aimed to investigate the potential causes for non-iatrogenic CAVB in young patients, as well as to identify possible predictors for need of implantable cardioverter-defibrillator (ICD) or permanent pacemaker (PPM) implantation in young patients presenting with CAVB.

Methods
Using the National Inpatient Sample (NIS) database, we identified patients aged 18–60 hospitalized with CAVB in the US between 2015 (last quarter)-2019. Patients who had concurrent cardiac surgery or electrophysiological procedures were excluded. Baseline demographics, clinical characteristics, potential etiologies for CAVB as well as outcomes including the need for temporary cardiac pacing (TCP), ICD and PPM implantation were analyzed. Multivariable logistic regression models were used to identify predictors of ICD or PPM implantation in patients with unknown etiology.

Results and discussion
An estimated total of 56,385 patients aged 18–60 with CAVB and no concurrent surgical or EP interventions were identified. The mean (±SD) age was 49 (±10) years and 59% were males. Approximately 55% of patients had no identified cause for CAVB (Table 1). While 16% of patients received TCP, 32% and 6% of patients were eventually implanted with a PPM and ICD, respectively (Figure 1), In patients with CAVB of unknown etiology, advanced age and need for TCP emerged in multivariable analyses as independent predictors of the need for both PPM and ICD implantation. Female gender was identified as a predictor for PPM implantation but was associated with a lower chance of ICD implantation.

Conclusion
The majority of non-iatrogenic young CAVB patients had no identified etiology in a nationwide database and less than 40% of the patients received an implantable cardiac device. Better risk stratification and diagnostic algorithms are needed for this population of patients.

Funding Acknowledgement
Type of funding sources: None.